Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
Status:
Closed
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
S1512 is permanently closed to accrual effective June 4, 2021.
NCT#02775851
